AIM ImmunoTech, Inc. (AIM)
| Market Cap | 83.00M |
| Revenue (ttm) | 171,000 |
| Net Income (ttm) | -11.67M |
| Shares Out | 38.91M |
| EPS (ttm) | -5.87 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $2.04 |
| Previous Close | $2.02 |
| Change ($) | 0.02 |
| Change (%) | 0.99% |
| Day's Open | 2.00 |
| Day's Range | 1.97 - 2.08 |
| Day's Volume | 1,399,436 |
| 52-Week Range | 0.83 - 6.10 |
AIM to discuss AMP-511 trial which includes COVID-19-induced chronic fatigue “long hauler” patients and other upcoming milestones AIM to discuss AMP-511 trial which includes COVID-19-induced c...
OCALA, Fla., Jan. 11, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) and its CEO Thomas K. Equels today announced that this week's planned investor conference call will be p...
AIM to host investor conference call on January 12, 2021 at 11AM ET to discuss developments with AMP-511 trial and provide update on other major achievements and upcoming milestones AIM to hos...
Institutional Review Board Authorizes Public Notification for Potential Enrollment of Subjects Institutional Review Board Authorizes Public Notification for Potential Enrollment of Subjects
AIM ImmunoTech Announces Availability of the ME/CFS Clinical Trial of its Drug Ampligen for Enrollment to COVID-19 ‘Long Haulers' Institutional Review Board Authorizes Public Notification for ...
OCALA, Fla., Dec. 21, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat immune disord...
AIM ImmunoTech (NYSE: AIM) shares are trading higher on Wednesday after the company dosed its first patient in a study evaluating ampligen as part of combination treatment for patients with ca...
OCALA, Fla., Nov. 25, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced developments in its work to develop new treatments or preventive strategies for COVID-19...
OCALA, Fla., Nov. 13, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat immune disord...
Early Onset Therapy May Be Key to COVID Long Hauler Syndrome Early Onset Therapy May Be Key to COVID Long Hauler Syndrome
TAMPA, Fla. and OCALA, Fla., Oct. 30, 2020 (GLOBE NEWSWIRE) -- BioFlorida has announced Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech Inc. (NYSE American: AIM), as its Weaver H. ...
OCALA, Fla. , Oct. 22, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech, is scheduled to parti...
COVID-19 Patients May Continue to Experience Chronic Fatigue-Like Symptoms COVID-19 Patients May Continue to Experience Chronic Fatigue-Like Symptoms
Aim ImmunoTech (AIM) is in the news Tuesday after positive results from an Early Access Program (EAP) sent AIM stock soaring higher. The post Aim ImmunoTech News: Why AIM Stock Is Shooting 22%...
One of the things that's been keeping interest in AIM somewhat strong since that March plunge is that no company has pinned down an effective coronavirus treatment or vaccine. It's not a stret...
As the Nasdaq continues its historic climb, the Dow has erased some of Monday's gains. The coronavirus will continue to make headlines as its cases grow at a consistent rate across 23 states.
Cheap stocks are effectively Wall Street's casino.
AIM stock has entered Wall Street’s consciousness due to the underlying biotech firm’s potential coronavirus treatment. However, will this be enough to keep shares moving higher?
One big breakthrough moment in coronavirus research could bring wealth to AIM ImmunoTech. It could also bring big gains to AIM stock.
AIM ImmunoTech Inc. (NYSE: AIM) shares ticked higher on Thursday after the company announced some big developments with the U.S. Food and Drug Administration (FDA) concerning its treatment for...
Though AIM stock is relevant on paper, with competition raging in the race for a coronavirus treatment, along with AIM ImmunoTech's checkered past, this is a very speculative gamble. The post ...
If it sounds too good to be true, it probably is. And that's likely the case when you look deeper into what's going on with AIM ImmunoTech stock.
AIM ImmunoTech reported its 2019 results on March 31. Despite the coronavirus push, AIM stock headed lower on the news.
One of the few sectors that have enjoyed upside is the pharmaceutical industry. In particular, AIM stock has jumped on a possible Covid-19 treatment.
AIM stock was a big winner on hopes it could join the response to the coronavirus. But its history suggests those hopes are too optimistic.
Look for biotech stocks as a group to gain more than 20% this year … with the best, most innovative firms more than doubling.
AIM ImmunoTech (AIM) news for Monday concerning a possible treatment for the coronavirus from China has AIM stock rocketing higher.
The major U.S. stock market averages were all tumbling close to 5% and bond yields were hitting record lows Monday following oil's plunge in the wake of the wrangling between Saudi Arabia and ...
Ampligen® obtained 100% survival rate at clinically achievable human dosage levels for SARS in animal experiments
About AIM
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. It is also developing Ampligen for the treatment of Hepatitis B and HI... [Read more...]
| Industry Biotechnology | Founded 1966 |
| CEO Thomas Equels | Employees 24 |
| Stock Exchange NYSEAMERICAN | Ticker Symbol AIM |
Financial Performance
In 2019, AIM ImmunoTech's revenue was $140,000, a decrease of -61.85% compared to the previous year's $367,000. Losses were -$9.53 million, -2.99% less than in 2018.